Dr Reddy’s says US FDA issued Form 483 with two observations for its FTO-11 facility in Andhra Pradesh
AI Market Summary
Dr Reddy's reported a US FDA pre-approval inspection at its FTO-11 facility resulting in a Form 483 with two observations, which it plans to remediate on schedule. While not an approval denial, the observations introduce near-term regulatory overhang. The company also set an upcoming earnings release and call, with prior-quarter profitability pressured by semaglutide supply disruptions and US pricing competition, keeping focus on execution and compliance.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.54%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
India’s Dr Reddy’s Laboratories said the US Food and Drug Administration completed a pre-approval inspection at its FTO-11 manufacturing facility in Andhra Pradesh and issued a Form 483 with two observations. The company said it will respond and address the observations within the stipulated timeline. The stock closed down 1.86% in the prior session, and the company’s market capitalisation was about Rs 98,487 crore.
